Dr. Brufsky Discusses Bevacizumab Benefits In Tnbc

Dr. Brufsky Discusses Bevacizumab Benefits in TNBC

Dr. Brufsky Advises Doctors on Bevacizumab for Breast Cancer

Assessing the Use of Bevacizumab

Dr. Brufsky Discusses the tnAcity Trial

Targeted Oncology

Dr. Sikov on Bevacizumab or Carboplatin Impact On TNBC Subtype

Dr. Brufsky Discusses the tnAcity Trial

Dr. Brufsky Discusses Future Research into Bisphosphonates

Dr. Brufsky on the COLET Trial for Triple-Negative Breast Cancer

Dr. O'Shaughnessy on Avastin as Her Standard of Care

Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC

Role of Neoadjuvant Platinum-Based Therapy for TNBC

Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer

Targeted Oncology

Dr. Brufsky on Challenges in Breast Cancer

TNBC: the targeted therapy era

Cobimetinib Plus Paclitaxel in TNBC

Targeted Oncology

Dr. O'Shaughnessy on Continued Access to Avastin

How Avastin (Bevacizumab) Treats Metastatic Breast Cancer

Dr. Jason Konner Discusses Bevacizumab in Ovarian Cancer

Dr. Brufsky on Challenges Facing Biosimilars in Breast Cancer

Dr. Brufsky Discusses Resistance to HER2-Targeted Therapies